Ixovex-1

Ixovex-1 is a novel oncolytic adenovirus engineered for cancer-selective replication. It achieves this selectivity through a single point mutation in the E1B-93R 3' splice acceptor site, resulting in overexpression of the E1B-156R splice isoform. This modification enhances its ability to replicate preferentially within cancer cells while sparing normal cells. Unlike earlier oncolytic adenoviruses, Ixovex-1 retains a functional E3B region, which improves its efficacy in vivo. Preclinical studies have demonstrated that Ixovex-1 significantly inhibits tumor growth and prolongs survival in animal models of lung carcinoma. The drug is currently being evaluated as both a single agent and in combination with pembrolizumab for patients with locally advanced, unresectable, or metastatic solid tumors who have exhausted standard therapies[2][5][6]. The primary route of administration is intratumoral injection.